Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai Pharma to Build $1.8 Billion Novel Drug Facility in Zhangjiang Park

publication date: Jan 4, 2021

Shanghai Pharmaceuticals broke ground on a $1.8 billion, 3.2 million-square-foot industrial park that will add an increased focus on its novel drug development efforts. The company said the new site would develop cell and gene therapies and manufacture therapeutic antibodies. When completely built out, the facility will include 538,000 square feet for an incubation platform and another 861,000 square feet for antibody manufacturing. It will eventually house 120,000 liters of antibody reactors. More details....

Stock Symbols: (SHA: 601607; HK: 2607)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.